Sinovac Biotech’s EV71 Vaccine Passes Phase II Test

Sinovac Biotech announced positive top-line results from a Phase II clinical trial of the company’s inactivated vaccine for human enterovirus 71 (EV71), which causes hand, foot and mouth disease (HFMD). The vaccine showed good immunogenicity and a favorable safety profile with no vaccine-related serious adverse events. More details.... Stock Symbol: (NSDQ: SVA)     Share this with colleagues: